ArticleInternational journal of medical sciences2025
Integration of Multi-Scale Profiling and Machine Learning Reveals the Prognostic Role of Extracellular Matrix-Related Cancer-Associated Fibroblasts in Lung Adenocarcinoma.
Article in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- SPP1+ Macrophages and the Orchestration of Spatially Organized Immunosuppression in Cancer.Biomedicines · 2026Review
- SPP1 regulates tumor progression through modulation of signaling pathways and the tumor microenvironment.Discover oncology · 2025Review
- Single-cell RNA sequencing reveals heterogeneity among AT2 epithelial cells in the lung adenocarcinoma microenvironment.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality, necessitating novel therapeutic targets and prognostic strategies. This study investigates the role of extracellular matrix cancer-associated fibroblasts (eCAFs) and their interaction with SPP1+ macrophages in LUAD progression and prognosis. Utilizing single-cell RNA sequencing from 15 LUAD tumors and integrating multi-cohort transcriptomic data (TCGA, GSE31210, GSE72094), we identified eCAFs as a dominant CAF subtype in advanced-stage tumors and high-grade pathological subtypes, correlating with poor patient survival. Similarly, SPP1+ macrophages exhibited increased abundance in advanced tumors and adverse prognosis. Pseudotime trajectory analysis revealed eCAFs as an evolutionary endpoint in CAF differentiation, associated with extracellular matrix remodeling pathways (COLLAGEN, FN1). Cell-cell communication analysis highlighted eCAFs-SPP1+ macrophage interactions via COL1A1-CD44 and COL1A2-CD44 ligand-receptor pairs, suggesting a mechanism for immune-excluded microenvironments. A prognostic model incorporating 28 eCAFs-related genes, validated through 101-machine learning algorithms, effectively stratified patients into high- and low-risk groups across cohorts. This study underscores eCAFs as key drivers of LUAD progression and proposes their interplay with SPP1+ macrophages as a therapeutic target. The developed prognostic signature offers clinical utility for risk stratification, though further experimental validation is warranted. These findings advance understanding of stromal-immune crosstalk in LUAD and highlight ECM remodeling as a critical pathway in tumor evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.